Rx of Generics for Xarelto doubled in 1 yr

8 billion won in outpatient prescriptions in the first half

104% increase from 3.9 billion in the same period last year

Generics for Xarelto (Rivaroxaban) are rapidly increasing their prescription performance.

 

In the first half of last year, prescription sales of 8 billion won were recorded, more than doubling in one year.

 

On the other hand, the original product's prescription performance decreased by half during the same period.

 

Generics for Xarelto, 3.9 billion → 8 billion won growth in one year, original cut in half According to UBIST, a pharmaceutical market research institute on the 1st, the number of outpatient prescriptions for rivaroxaban in Korea in the first half of last year was 23.8 billion won, down 29% from 33.5 billion won in the same period last year.

 

During this period, Xarelto, the original product, decreased by 46% from 29.6 billion won to 15.9 billion won.

 

Xarelto's quarterly prescriptions peaked at 16.3 billion won in the third quarter of 2021, then steadily declined.

 

In particular, the drop has increased since the third quarter of 2022.

 

Prescription sales, which were 14.8 billion won in the second quarter of last year, plummeted to 11.8 billion won in the third quarter.

 

Analysts say that the drug price cut, which was delayed due to Bayer's administrative lawsuit and application for suspension of execution, took place at this time, leading to a sharp drop in prescriptions.

 

Since then, Xarelto's prescriptions have steadily declined.

 

In the fourth quarter of last year, prescription sales of 8 billion won fell below 10 billion won, and in the first and second quarters of this year, prescription sales were only 8 billion won and 7.8 billion won, respectively.

 

Xarelto generics are expanding.

 

In the first half of last year, Xarelto generics recorded a combined prescription of 8 billion won.

 

Compared to 3.9 billion won in the same period last year, it more than doubled in one year.

 

Generics for Xarelto first appeared in the second quarter of 2021.

 

Then, they exceeded 1 billion won in the first quarter of 2022 and 2 billion won in the second quarter, respectively.

 

In the fourth quarter of that year, it further increased to more than 3 billion won, and in the second quarter of this year, it recorded more than 4 billion won.

 

In the process, the share of generics also steadily increased.

 

In the second quarter of this year, generics accounted for 36% of the rivaroxaban ingredient market.

 

Compared to 13% in the second quarter of last year, it has nearly tripled in one year.

 

Analysts say that generics are succeeding in targeting the original.

 

Among generic products, Chong Kun Dang's Riroxia, Hanmi Pharm's Riroxban, and Samjin Pharm's Riroxaban posted sales of over W1bn in 1H.

 

Prescriptions for each product in 1H were 2.2 billion won for Riroxia, 1.5 billion won for Riroxban, and 1.3 billion won for Riroxaban.

 

Lixiana announces 100 billion won per year, Pradaxa's sluggishness continues Among the NOAC products other than Xarelto, Daiichi Sankyo's Lixiana produced the highest prescription performance.

 

Lixiana's prescription amount in the first half was 51.4 billion won, up 10% from 46.5 billion won in the first half of last year.

 

If this trend continues, Lixiana is expected to generate more than 100 billion won in prescriptions by the end of this year.

 

BMS Eliquis recorded prescription sales of KRW 38.3 billion in the first half.

 

Compared to 35.8 billion won in the first half of last year, it increased by 7% in one year.

 

Boehringer Ingelheim Pradaxa's slump is prolonged.

 

Pradaxa's prescriptions in the first half of this year were 5.9 billion won.

 

It decreased by 11% from 6.6 billion won in the first half of last year.

 

Pradaxa's quarterly prescriptions fell below 4 billion won in the third quarter of 2020 and further decreased to less than 3 billion won in the second quarter of this year.